A Phase 4 interventional study of Lyophilized Palivizumab and Liquid Palivizumab in Chronic Lung Disease, sponsored by MedImmune LLC. Completed at 54 sites in United States. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2018-06-27.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to measure the rate of anti-palivizumab antibodies (also referred to as immune reactivity or immunogenicity) in subjects receiving either the liquid or lyophilized formulation of palivizumab. This study will compare the number and percentage of subjects with anti-palivizumab antibodies receiving either the liquid or lyophilized formulation of palivizumab.
The approved liquid formulation of palivizumab was developed to simplify preparation of the drug before injection. Both formulations of palivizumab have been shown to be bioequivalent in children 6 months of age or younger with a history of chronic lung disease. In previous studies of liquid palivizumab, immunogenicity was evaluated up to 2 months after dosing in adults, and 1 month after dosing in children. In this study, MI-CP116, immunogenicity will be evaluated between 4 and 6 months after the last dose of study drug, in order to provide data at a time point significantly distant from dosing when drug interference is minimal.
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
First submitted before MedImmune LLC became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liquid Palivizumab
Biological: Liquid Palivizumab
Lyophilized Palivizumab
Biological: Lyophilized Palivizumab
Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
Also known as: Synagis
Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
Also known as: Synagis
Number and Percentage of Participants With Immune Reactivity
Presence of anti-palivizumab antibodies
Time frame: Day 240-300 follow up
A total of 417 subjects were randomized into the study at 51 sites in the United States between 20 October 2005 and 02 October 2007.
| Milestone | Liquid Palivizumab | Lyophilized Palivizumab |
|---|---|---|
| Started | 211 | 202 |
| Completed | 197 | 190 |
| Not completed | 14 | 12 |
| Withdrew: Lost to follow-up | 7 | 7 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Relocation | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Moved to dom. republic | 1 | 0 |
Presence of anti-palivizumab antibodies
| Participants | Liquid Palivizumab | Lyophilized Palivizumab | Combined Liquid/Lyophilized Palivizumab |
|---|---|---|---|
| Number | 0 | 1 | 1 |
| Percentage | 0.0 | 0.5 | 0.3 |
Collected over Serious adverse events were collected from the time of the first study drug administration through Study Day 150. Adverse events were not collected in this study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liquid Palivizumab | — | 18/211 (8.5%) | 0/211 (0%) |
| Lyophilized Palivizumab | — | 12/202 (5.9%) | 0/202 (0%) |
| Event | Liquid Palivizumab | Lyophilized Palivizumab |
|---|---|---|
| BronchiolitisInfections and infestations | 6/211 | 3/202 |
| GastroenteritisInfections and infestations | 2/211 | 2/202 |
| Respiratory DistressRespiratory, thoracic and mediastinal disorders | 0/211 | 2/202 |
| Viral InfectionInfections and infestations | 2/211 | 0/202 |
| Cleft LipCongenital, familial and genetic disorders | 1/211 | 1/202 |
| Inguinal HerniaGastrointestinal disorders | 1/211 | 1/202 |
| AbscessInfections and infestations | 0/211 | 1/202 |
| Occult Blood PositiveGastrointestinal disorders | 0/211 | 1/202 |
| Failure to ThriveMetabolism and nutrition disorders | 0/211 | 1/202 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 0/211 | 1/202 |
| Age, Continuous(months) | Liquid Palivizumab | Lyophilized Palivizumab | Total |
|---|---|---|---|
| Mean | 4.56 ± 4.50 | 4.00 ± 4.16 | 4.29 ± 4.34 |
| Sex: Female, Male(Participants) | Liquid Palivizumab | Lyophilized Palivizumab | Total |
|---|---|---|---|
| Female | 104 | 99 | 203 |
| Male | 107 | 103 | 210 |
| Region of Enrollment(participants) | Liquid Palivizumab | Lyophilized Palivizumab | Total |
|---|---|---|---|
| United States | 211 | 202 | 413 |
| Chronic Lung Disease at Prematurity(Participants) | Liquid Palivizumab | Lyophilized Palivizumab | Total |
|---|---|---|---|
| Yes | 35 | 26 | 61 |
| No | 176 | 176 | 352 |
| Race/Ethnicity(Participants) | Liquid Palivizumab | Lyophilized Palivizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 25 | 24 | 49 |
| White | 151 | 149 | 300 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Hispanic | 22 | 14 | 36 |
| Other | 12 | 12 | 24 |
| Gestational Age at Birth(Weeks) | Liquid Palivizumab | Lyophilized Palivizumab | Total |
|---|---|---|---|
| Mean | 32.4 ± 2.7 | 32.7 ± 2.5 | 32.5 ± 2.6 |
| Weight at Day 0(Kilogram) | Liquid Palivizumab | Lyophilized Palivizumab | Total |
|---|---|---|---|
| Mean | 5.326 ± 2.274 | 5.079 ± 2.264 | 5.205 ± 2.270 |
The record gives a start of Oct 2005, a primary completion of Oct 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2008, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palivizumab